X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (796) 796
cdc2 protein kinase - metabolism (626) 626
animals (624) 624
phosphorylation (527) 527
cdc2 protein kinase - antagonists & inhibitors (523) 523
index medicus (436) 436
cell biology (382) 382
cell cycle (350) 350
biochemistry & molecular biology (307) 307
mitosis (266) 266
cell line, tumor (252) 252
enzyme inhibitors - pharmacology (250) 250
oncology (236) 236
mice (232) 232
apoptosis (230) 230
female (223) 223
cyclin-dependent kinases - antagonists & inhibitors (207) 207
cancer (190) 190
cell-cycle (185) 185
cyclin-dependent kinases (177) 177
apoptosis - drug effects (174) 174
cell cycle - drug effects (170) 170
cyclin b - metabolism (164) 164
activation (156) 156
antineoplastic agents - pharmacology (155) 155
cell cycle proteins - metabolism (152) 152
cdc2 protein kinase - genetics (145) 145
cyclin-dependent kinases - metabolism (144) 144
protein kinase inhibitors - pharmacology (143) 143
protein-kinase (140) 140
expression (139) 139
cdc2 (136) 136
hela cells (136) 136
proteins (136) 136
tumor cells, cultured (136) 136
cdc2 protein kinase (134) 134
protein-serine-threonine kinases - metabolism (133) 133
kinases (125) 125
purines - pharmacology (122) 122
cell proliferation - drug effects (120) 120
protein-serine-threonine kinases - antagonists & inhibitors (117) 117
mitosis - drug effects (116) 116
cell line (112) 112
signal transduction (111) 111
research (109) 109
male (106) 106
cyclin b1 (105) 105
cyclins - metabolism (103) 103
cell division - drug effects (102) 102
chemistry, medicinal (101) 101
phosphorylation - drug effects (101) 101
cyclin-dependent kinase 2 (99) 99
article (97) 97
g2 phase - drug effects (97) 97
cells, cultured (95) 95
blotting, western (92) 92
molecular sequence data (92) 92
cell cycle proteins - genetics (88) 88
structure-activity relationship (88) 88
cdc2 kinase (86) 86
research article (85) 85
cell division (83) 83
kinase (83) 83
enzyme activation (79) 79
cdk1 (77) 77
dose-response relationship, drug (77) 77
protein kinases - metabolism (77) 77
rats (77) 77
amino acid sequence (76) 76
cdc2-cdc28 kinases (76) 76
cell proliferation (76) 76
protein-tyrosine kinases - metabolism (76) 76
dna damage (75) 75
cell cycle - physiology (74) 74
cell cycle proteins - antagonists & inhibitors (73) 73
developmental biology (72) 72
flow cytometry (72) 72
multidisciplinary sciences (72) 72
nuclear proteins - metabolism (72) 72
mutation (71) 71
time factors (71) 71
mitosis - physiology (70) 70
protein-tyrosine kinases - antagonists & inhibitors (70) 70
cell cycle proteins (69) 69
cell survival - drug effects (69) 69
in-vitro (69) 69
biology (68) 68
g2 phase (68) 68
protein binding (67) 67
rna interference (67) 67
genetics & heredity (66) 66
cells (65) 65
cyclin-dependent kinase (65) 65
gene expression (65) 65
s-phase (65) 65
analysis (64) 64
inhibition (64) 64
okadaic acid (64) 64
pharmacology & pharmacy (64) 64
phosphoprotein phosphatases - antagonists & inhibitors (64) 64
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Biology of the Cell, ISSN 1059-1524, 04/2011, Volume 22, Issue 8, pp. 1191 - 1206
Mitosis requires precise coordination of multiple global reorganizations of the nucleus and cytoplasm. Cyclin-dependent kinase 1 (Cdk1) is the primary upstream... 
ANAPHASE-PROMOTING COMPLEX | XENOPUS EGG EXTRACTS | PROTEIN PHOSPHATASES | CYCLE-DEPENDENT PHOSPHORYLATION | UBIQUITIN LIGASE | M-PHASE | CHROMOSOME ALIGNMENT | CELL-CYCLE | TUMOR-CELLS | SPINDLE-ASSEMBLY CHECKPOINT | CELL BIOLOGY | Cyclin-Dependent Kinases - metabolism | Gene Expression - drug effects | Xenopus Proteins - genetics | Mitosis | Protein-Tyrosine Kinases - metabolism | Humans | Phosphoprotein Phosphatases - metabolism | G2 Phase - drug effects | CDC2 Protein Kinase - metabolism | Cell Cycle Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - genetics | Cyclin B - genetics | cdc25 Phosphatases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Prometaphase - drug effects | Female | Cyclin-Dependent Kinases - antagonists & inhibitors | Phosphorylation - drug effects | cdc25 Phosphatases - metabolism | Cyclin-Dependent Kinases - genetics | Nuclear Proteins - genetics | Protein-Serine-Threonine Kinases - metabolism | CDC2 Protein Kinase - genetics | Protein Phosphatase 2 - antagonists & inhibitors | CDC2 Protein Kinase - antagonists & inhibitors | Xenopus laevis | Cell Cycle Proteins - metabolism | Protein Phosphatase 2 - genetics | Protein-Serine-Threonine Kinases - genetics | Nuclear Proteins - metabolism | Phosphoprotein Phosphatases - antagonists & inhibitors | cdc25 Phosphatases - genetics | Xenopus Proteins - antagonists & inhibitors | Membrane Proteins | Animals | Phosphoprotein Phosphatases - genetics | Nuclear Proteins - antagonists & inhibitors | Protein Phosphatase 2 - metabolism | Cyclin B - metabolism | Feedback, Physiological - drug effects | Xenopus Proteins - metabolism | Protein Kinase Inhibitors - pharmacology | S Phase - drug effects | HeLa Cells | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 10/2016, Volume 12, Issue 10, pp. 876 - 884
Journal Article
BMC Cancer, ISSN 1471-2407, 01/2014, Volume 14, Issue 1, p. 32
Background: Although MYC is an attractive therapeutic target for breast cancer treatment, it has proven challenging to inhibit MYC directly, and clinically... 
Cyclin-dependent kinase | Breast cancer | Synthetic lethality | MYC | SYNTHETIC LETHAL | C-MYC | TUMOR-CELLS | PROLIFERATION | INHIBITION | GENE | ONCOLOGY | PATHWAY | ESTROGEN | THERAPEUTIC TARGETS | EXPRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Phosphorylation | Cyclin-Dependent Kinase 4 - genetics | Humans | Molecular Targeted Therapy | CDC2 Protein Kinase - metabolism | Dose-Response Relationship, Drug | Breast Neoplasms - enzymology | Transfection | Bcl-2-Like Protein 11 | RNA Interference | Female | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Cell Death - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins - metabolism | Cyclin-Dependent Kinase 2 - metabolism | CDC2 Protein Kinase - genetics | CDC2 Protein Kinase - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - genetics | Tumor Suppressor Protein p53 - metabolism | Cyclin-Dependent Kinase 2 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Proto-Oncogene Proteins c-myc - metabolism | Apoptosis Regulatory Proteins - metabolism | Breast Neoplasms - genetics | Signal Transduction - drug effects | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Cell Line, Tumor | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Care and treatment | Patient outcomes | Cancer cells | Physiological aspects | Genetic aspects | Research | Risk factors | Cyclins
Journal Article
Cell Reports, ISSN 2211-1247, 12/2015, Volume 13, Issue 11, pp. 2425 - 2439
To identify therapeutic targets for glioblastoma (GBM), we performed genome-wide CRISPR-Cas9 knockout (KO) screens in patient-derived GBM stem-like cells... 
WEE1 | CRISPR-Cas9 | Glioblastoma | cancer therapeutics | functional genomics | PKMYT1 | gene editing | Myt1 | Cancer therapeutics | Gene editing | Functional genomics | ACTIVATION | PROTEIN | GENE-EXPRESSION | GOLGI | PHOSPHORYLATES CDC2 | HUMAN MYT1 | INHIBITORY KINASE | BRAIN | RNAI SCREEN | REQUIREMENT | CELL BIOLOGY | Neoplastic Stem Cells - cytology | Phosphorylation | Mitosis | Protein-Tyrosine Kinases - metabolism | Humans | Microscopy, Video | Time-Lapse Imaging | Tumor Suppressor Protein p53 - genetics | CDC2 Protein Kinase - metabolism | Cell Cycle Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - genetics | Receptor, Epidermal Growth Factor - metabolism | Neoplastic Stem Cells - metabolism | RNA Interference | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Glioblastoma - metabolism | Membrane Proteins - metabolism | Nuclear Proteins - genetics | Proto-Oncogene Proteins c-akt - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Cell Survival - drug effects | Gene Library | CDC2 Protein Kinase - antagonists & inhibitors | Membrane Proteins - genetics | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Tumor Suppressor Protein p53 - metabolism | Nuclear Proteins - metabolism | Pyrimidines - pharmacology | CRISPR-Cas Systems - genetics | Membrane Proteins - antagonists & inhibitors | Glioblastoma - pathology | Nuclear Proteins - antagonists & inhibitors | Cyclin B - metabolism | Genome, Human | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Cell Death and Differentiation, ISSN 1350-9047, 03/2012, Volume 19, Issue 3, pp. 369 - 377
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2016, Volume 113, Issue 50, pp. E8051 - E8058
Protein–protein interactions play a central role in cellular function. Improving the understanding of complex formation has many practical applications,... 
Druggable surface | Direct coupling analysis | Drug design | Protein-protein interface | Hot spots | drug design | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | DIMERIZATION | protein-protein interface | INHIBITION | CONSERVATION | hot spots | CDK1 | HOT-SPOTS | direct coupling analysis | HIV-1 PROTEASE | BINDING-SITES | WEB SERVER | druggable surface | COMPUTATIONAL PREDICTION | Histone Deacetylase 1 - chemistry | Molecular Probes | HIV Protease - drug effects | Humans | Proto-Oncogene Proteins c-mdm2 - chemistry | CDC2-CDC28 Kinases - antagonists & inhibitors | Repressor Proteins - antagonists & inhibitors | HIV Protease Inhibitors - pharmacology | Proto-Oncogene Proteins c-mdm2 - drug effects | CDC2 Protein Kinase - drug effects | Drug Design | Histone Deacetylase 1 - drug effects | CDC2 Protein Kinase - chemistry | Histone Deacetylase 1 - antagonists & inhibitors | Binding Sites | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Molecular Docking Simulation - methods | Repressor Proteins - chemistry | Protein Interaction Domains and Motifs - drug effects | CDC2 Protein Kinase - antagonists & inhibitors | HIV-1 - drug effects | CDC2-CDC28 Kinases - chemistry | CDC2-CDC28 Kinases - drug effects | Histone Deacetylases - chemistry | HIV Protease Inhibitors - chemistry | Tumor Necrosis Factor-alpha - chemistry | Tumor Necrosis Factor-alpha - drug effects | HIV-1 - enzymology | Histone Deacetylases - drug effects | Repressor Proteins - drug effects | HIV Protease - chemistry | Protein Multimerization - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Evolution, Molecular | Observations | Protein-protein interactions | Biological Sciences | PNAS Plus | protein−protein interface
Journal Article
Nature Cell Biology, ISSN 1465-7392, 01/2011, Volume 13, Issue 1, pp. 87 - 94
Journal Article
Science, ISSN 0036-8075, 9/2009, Volume 325, Issue 5948, pp. 1682 - 1686
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2013, Volume 19, Issue 10, pp. 2677 - 2687
Purpose: To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug. Experimental Design: Utilizing different multiple myeloma cell lines we... 
MULTIPLE-MYELOMA | CANCER-CELLS | ACTIVATION | ONCOLOGY | INDUCED APOPTOSIS | CYCLIN D1 | PHOSPHORYLATION | SENSITIVITY | TRANSDUCTION | DEPENDENT KINASE INHIBITOR | EXPRESSION | Cell Cycle - genetics | Gene Expression Regulation, Enzymologic - drug effects | Cyclin-Dependent Kinases - metabolism | Humans | Cell Survival - genetics | Thalidomide - pharmacology | Heterocyclic Compounds, 4 or More Rings - pharmacology | CDC2 Protein Kinase - metabolism | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Mitogen-Activated Protein Kinase 7 - antagonists & inhibitors | Female | Cyclin-Dependent Kinases - antagonists & inhibitors | Gene Expression Regulation, Neoplastic - drug effects | Cyclin-Dependent Kinases - genetics | Multiple Myeloma - enzymology | Cell Survival - drug effects | Cyclin-Dependent Kinase 2 - metabolism | CDC2 Protein Kinase - genetics | Bortezomib | CDC2 Protein Kinase - antagonists & inhibitors | Cyclin-Dependent Kinase 9 - genetics | Cyclin-Dependent Kinase 2 - genetics | Cyclin-Dependent Kinase 9 - antagonists & inhibitors | Mitogen-Activated Protein Kinase 7 - genetics | Mitogen-Activated Protein Kinase 7 - metabolism | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Drug Synergism | Xenograft Model Antitumor Assays | Multiple Myeloma - pathology | Animals | Cell Line, Tumor | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cyclin-Dependent Kinase 9 - metabolism | Protein Kinase Inhibitors - pharmacology | Multiple Myeloma - prevention & control | Cell Cycle - drug effects | Pyrazines - pharmacology | Boronic Acids - pharmacology
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 01/2001, Volume 276, Issue 1, pp. 251 - 260
Journal Article